A pathomics model for predicting response to chemo-immunotherapy in lung squamous cell carcinoma: A multicenter study [0.03%]
一项基于病理组学的模型预测肺鳞癌化疗联合免疫治疗应答的多中心研究
Dongying Wang,Shuai Mu,Minghui Zhang et al.
Dongying Wang et al.
Background: The identification of lung squamous cell carcinoma (LUSC) patients who may benefit from first-line chemo-immunotherapy (CIT) remains a challenge. This study aimed to develop a pathomics model to predict the T ...
Identifying eligible patients for the Australian national lung cancer screening program in primary care: A cross-sectional study using clinical decision support systems and evaluating PLCOm2012 data quality [0.03%]
利用临床决策支持系统识别澳大利亚全国肺癌筛查项目适行对象的研究及评估PLCOm2012数据质量的横断面研究
Lucas De Mendonça,Shakira Onwuka,Sarah York et al.
Lucas De Mendonça et al.
Primary care is pivotal in identifying eligible participants for Australia's National Lung Cancer Screening Program (NLCSP). Clinical Decision Support Systems (CDSS) can assist by flagging potentially eligible individuals using Electronic M...
Corrigendum to "Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)" [Lung Cancer 210 (2025) 108840] [0.03%]
加拿大小细胞肺癌数据库（CASCADE）中局限期小细胞肺癌的治疗及结局一文勘误通知
William J Phillips,Luna Jia Zhan,Deepro Chowdhury et al.
William J Phillips et al.
Published Erratum
Lung cancer (Amsterdam, Netherlands). 2025 Dec 16:108875. DOI:10.1016/j.lungcan.2025.108875 2025
Global patterns and trends in mesothelioma incidence: A retrospective cross-sectional study [0.03%]
全球间皮瘤发病率模式和趋势的回顾性横断面研究
Leiwen Fu,Ke Liu,Yang Liu et al.
Leiwen Fu et al.
Background: Mesothelioma is a rare and aggressive malignancy primarily caused by asbestos exposure; it predominantly affects older adults with a history of occupational contact. ...
Prognostic comparison of lymph node metastasis subtypes in lung adenocarcinoma: clinical implications of intranodal metastasis versus extranodal extension for optimizing R classification [0.03%]
肺腺癌淋巴结转移亚型的预后比较：淋巴结内转移与淋巴结外侵犯的临床意义及优化R分类
Jia-Yong Wu,Guo-Zhong Liang,Tian-Qing Chen et al.
Jia-Yong Wu et al.
Background: Lung adenocarcinoma (LUAD) prognosis is strongly influenced by lymph node (LN) status. While extranodal extension (ENE) is a recognized negative prognostic factor, the International Association for the Study o...
Reply to letter to the editor "The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell lung cancer" [0.03%]
来信“派姆单抗联合或不联合培美曲塞作为晚期非鳞状非小细胞肺癌诱导治疗后的维持治疗的有效性”的回信
Bas J M Peters,Stefan Böhringer,Esmee van Geffen
Bas J M Peters
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer [0.03%]
关于Durvalumab联合化疗并联用或不联用Oleclumab治疗初治的转移性非小细胞肺癌（NSCLC）患者的Ⅲ期研究（MAGELLAN arms B1和B3）
Byoung Chul Cho,Chaiyut Charoentum,Dong-Wan Kim et al.
Byoung Chul Cho et al.
Objectives: Standard-of-care therapies for metastatic non-small-cell lung cancer (mNSCLC) have mixed outcomes that remain unsatisfactory. Durvalumab (anti-PD-L1) plus oleclumab (anti-CD73) might provide a synergistic anti...
Informed choice for lung cancer screening: A randomised trial of three decision support tools [0.03%]
有关肺癌筛查的知情选择：三种决策支持工具的随机试验
Rachael H Dodd,Marianne Weber,Kathleen McFadden et al.
Rachael H Dodd et al.
Shared decision-making in the Australian National Lung Cancer Screening Program (NLCSP) involves consultation between healthcare provider and individual to ensure participants make an informed choice about screening. Three decision support ...
Treatment response after induction therapy in advanced thymic tumors: results from the Italian nationwide TYME database [0.03%]
意大利全国TYME数据库中诱导治疗后晚期胸腺肿瘤的治疗反应结果分析
Giovanni Leuzzi,Federica Sabia,Claudia Proto et al.
Giovanni Leuzzi et al.
Background: Induction therapy (IT) prior to surgery is a key strategy to improve resectability in advanced thymic tumors (ATTs). This study aimed to assess prognostic factors and the impact of IT on clinical outcomes. ...
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS [0.03%]
关于Tarlatamab给药及管理CRS/ICANS的多机构观点
Bingnan Zhang,Laura Alder,Samuel Rosner et al.
Bingnan Zhang et al.
Background: Tarlatamab, a bispecific T-cell engager, is the first treatment in many years to significantly improve overall survival in relapsed extensive stage small cell lung cancer (ES-SCLC). However, implementation of ...